Workflow
CCHT(000661)
icon
Search documents
长春高新(000661) - 关于子公司鼻喷流感减毒活疫苗上市许可申请获得批准的公告
2025-08-25 11:02
证券代码:000661 证券简称:长春高新 公告编号:2025-073 长春高新技术产业(集团)股份有限公司 关于子公司鼻喷流感减毒活疫苗上市许可申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 近日,长春高新技术产业(集团)股份有限公司(以下简称"公司")子公司 ——长春百克生物科技股份公司(以下简称"百克生物")收到国家药品监督管理 局下发的鼻喷流感减毒活疫苗《药品注册证书》。现将相关情况公告如下: 一、《药品注册证书》的主要信息 受理号:CXSS2400043 证书编号:2025S02547 药品名称:鼻喷流感减毒活疫苗 百克生物本次获批的鼻喷流感减毒活疫苗可通过鼻腔接种模拟流感病毒自然 感染的方式,在呼吸道形成预防流感病毒入侵的第一道免疫屏障。该疫苗在其已上 1 市冻干鼻喷流感减毒活疫苗产品基础上进行了剂型改良,由原冻干剂型升级为液体 剂型,使用过程中无需复溶步骤,接种更加便利,适用人群为 3(36 月龄)~17 岁人群。 剂型:鼻用制剂 规格:每支 0.2ml。每 1 次人用剂量为 0.2ml,含 A(H1N1)型和 A(H3N2) ...
创新药产业链多家龙头半年盈喜,“全球新”资产加速奔跑
ZHONGTAI SECURITIES· 2025-08-25 09:14
创新药产业链多家龙头半年盈喜, "全球新"资产加速奔跑 行业-市场走势对比 迎来产业加速发展期》2025-08-21 2、《创新药械行情持续,细分赛道 景气度提升》2025-08-17 3、《创新药械长牛,把握业绩、技 2025-08-11 | 评级: | 增持(维持) | | | 重点公司基本状况 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | 分析师:祝嘉琦 | | | | (元) | 2023A | 2024A | 2025E | 2026E | 2027E | 2023A | 2024A | 2025E | 2026E | 2027E | | | 执业证书编号:S0740519040001 | | | 药明生物 | 32.92 | 0.84 | 0.82 | 0.97 | 1.19 | 1.49 | 39. ...
长春高新股价微跌0.15% 子公司双抗ADC药物获批临床
Jin Rong Jie· 2025-08-22 18:08
Core Viewpoint - Changchun High-tech's stock price is experiencing a slight decline, reflecting market fluctuations and investor sentiment in the biopharmaceutical sector [1] Company Overview - Changchun High-tech operates in the biopharmaceutical industry, focusing on the production and sales of biological drugs and traditional Chinese medicine [1] - The company's core subsidiary, Jinsai Pharmaceutical, specializes in the research and development of genetically engineered biological drugs, including a series of growth hormone products [1] Recent Developments - Jinsai Pharmaceutical's application for clinical trials of the self-developed injection GenSci143 has been accepted by the National Medical Products Administration [1] - GenSci143 is a bispecific antibody-drug conjugate targeting B7-H3 and PSMA, which has potential dual therapeutic effects in targeted chemotherapy and tumor immunotherapy [1] Financial Performance - On the trading day, Changchun High-tech's stock price was reported at 103.33 yuan, with a maximum of 103.99 yuan and a minimum of 102.90 yuan, and a trading volume of 574 million yuan [1] - The company experienced a net outflow of 55.31 million yuan in principal funds on that day, with a cumulative net outflow of 107 million yuan over the past five days [1]
股市直播|000651,每10股派20元!分红超百亿
今日提示 重要新闻提示 格力电器(000651):实施2024年年度权益分派方案,向全体股东每10股派20元(含税),共计派发现 金红利111.7亿元 中国石化:拟5亿元—10亿元回购公司A股股票;2025年半年度合计拟派发现金股利106.70亿元(含税) 飞鹿股份:公司控股股东、实际控制人正在筹划控制权变更相关事宜,今日停牌 北交所新股能之光(920056)今日上市。 今日有2380亿元7天期逆回购到期。 恒生指数有限公司今日将宣布2025年第二季度之恒生指数系列检讨结果。 第33届广州博览会8月22日至24日举行。 华为兆瓦超充高质量发展峰会今日举行,将发布百兆瓦级重卡超充站。 国泰海通将于今日的日终清算后实施法人切换、客户及业务迁移合并,将原海通证券的相关法人主体切 换为国泰海通,适时将原海通证券的客户及业务迁移合并入国泰海通。 财经新闻 1. 8月21日,国家能源局发布7月份全社会用电量等数据。7月,全社会用电量10226亿千瓦时,同比增长 8.6%。从产业用电看,第一产业用电量170亿千瓦时,同比增长20.2%;第二产业用电量5936亿千瓦 时,同比增长4.7%;第三产业用电量2081亿千瓦时,同比 ...
长春高新子公司注射用GenSci143注册临床试验申请获受理
长春高新(000661)8月21日晚公告,公司子公司长春金赛药业有限责任公司(简称"金赛药业")收到国 家药品监督管理局核准签发的《受理通知书》,金赛药业注射用GenSci143注册临床试验申请获得受 理。 据介绍,GenSci143是由金赛药业自主研发的一款靶向B7-H3与PSMA的双特异性抗体偶联药物 (BsADC),具有靶向化疗和肿瘤免疫双重潜在治疗作用。GenSci143通过结合B7-H3或PSMA,内化至溶 酶体,释放TOPO-I抑制剂毒素,实现对B7-H3阳性、PSMA阳性及双阳性肿瘤细胞的杀伤。B7-H3和 PSMA双靶点协同作用,能够克服肿瘤异质性和由单个靶点表达降低导致的耐药,从而覆盖更多患者并 产生更持久的抗肿瘤药效。GenSci143采用自主研发的接头技术,具有毒素活性强和连接子血浆稳定性 高等特性,在产生更强肿瘤杀伤作用的同时,还具备更优的潜在安全性。 GenSci143凭借其创新的双靶点设计、稳定的连接子技术、高效的细胞杀伤机制和广泛的抗肿瘤谱,或 可为多种B7-H3和/或PSMA表达的实体瘤提供新的治疗方向。 长春高新8月11日晚公告,公司控股子公司金赛药业近日收到国家药品监督管理 ...
长春高新:子公司注射用GenSci143注册临床试验申请获得受理
Mei Ri Jing Ji Xin Wen· 2025-08-21 10:33
Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance for the clinical trial application of GenSci143 by the National Medical Products Administration, indicating progress in the development of a new targeted therapy for certain tumors [2] Company Summary - Jinsai Pharmaceutical, a subsidiary of Changchun High-tech, is developing GenSci143, a bispecific antibody-drug conjugate targeting B7-H3 and PSMA, which may offer dual therapeutic potential in targeted chemotherapy and tumor immunotherapy [2] - The drug is expected to provide new treatment options for various solid tumors expressing B7-H3 and/or PSMA [2]
长春高新:子公司注射用GenSci143注册临床试验申请获受理
人民财讯8月21日电,长春高新(000661)8月21日晚间公告,公司子公司长春金赛药业有限责任公司 (简称"金赛药业")近日收到国家药品监督管理局核准签发的《受理通知书》,金赛药业注射用GenSci143 注册临床试验申请获得受理。GenSci143是由长春金赛药业自主研发的一款靶向B7-H3与PSMA的双特异 性抗体偶联药物(BsADC),具有靶向化疗和肿瘤免疫双重潜在治疗作用。 ...
长春高新(000661) - 关于子公司注射用GenSci143注册临床试验申请获得受理的公告
2025-08-21 10:31
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 近日,长春高新技术产业(集团)股份有限公司(以下简称"公司")子公 司——长春金赛药业有限责任公司(以下简称"金赛药业")收到国家药品监督 管理局核准签发的《受理通知书》,金赛药业注射用 GenSci143 注册临床试验申 请获得受理,现将相关情况公告如下: 一、药品的基本情况 产品名称:注射用 GenSci143 申请事项:境内生产药品注册临床试验 受理号:CXSL2500728 证券代码:000661 证券简称:长春高新 公告编号:2025-072 长春高新技术产业(集团)股份有限公司 关于子公司注射用 GenSci143 注册临床试验申请 获得受理的公告 1 肾、十二指肠等)中表达水平很低,但在前列腺癌组织中的表达比正常组织高 100-1000 倍,被认为是前列腺癌的理想的诊断和治疗靶点。此外,PSMA 在其他 实体肿瘤血管内皮细胞中也有表达,例如肺癌、胃癌、胰腺癌、乳腺癌、结直肠 癌等。 GenSci143 是由长春金赛药业自主研发的一款靶向 B7-H3 与 PSMA 的双特异 性抗体偶联药物(BsADC ...
长春高新:子公司注射用 GenSci143 注册临床试验申请获受理
Xin Lang Cai Jing· 2025-08-21 10:29
长春高新公告,子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《受理通知 书》,金赛药业注射用 GenSci143 注册临床试验申请获得受理。GenSci143 是一款靶向 B7-H3 与 PSMA 的双特异性抗体偶联药物(BsADC),具有靶向化疗和肿瘤免疫双重潜在治疗作用。该药物通过结合 B7-H3 或 PSMA,内化至溶酶体,释放 TOPO-I 抑制剂毒素,实现对 B7-H3 阳性、PSMA 阳性及双阳性 肿瘤细胞的杀伤。GenSci143 采用自主研发的接头技术,具有毒素活性强和连接子血浆稳定性高等特 性,在产生更强肿瘤杀伤作用的同时,还具备更优的潜在安全性。 ...
创新药械行情持续,细分赛道景气度提升
ZHONGTAI SECURITIES· 2025-08-17 12:31
Investment Rating - The industry investment rating is "Overweight (Maintain)" [2] Core Viewpoints - The innovative pharmaceutical and medical device market continues to thrive, with an increase in the prosperity of segmented tracks. The Shanghai Composite Index rose by 2.37%, while the pharmaceutical and biological sector increased by 3.08%, ranking 10th among 31 primary sub-industries. The pharmaceutical sector has shown strong recovery and continuity, aligning with previous predictions that declines would be short-lived and shallow [4][8][5]. - The market remains focused on innovative pharmaceuticals and medical devices, with significant events catalyzing the sector. Key highlights include a price increase of up to 170% for Eli Lilly's weight loss drug Mounjaro in the UK and the announcement of pivotal clinical trial results for a dual-target antibody by CanSino Biologics [4][8][5]. - Recommendations for investment focus on specific segments such as GLP-1 drugs, second-generation IO companies, and innovative medical devices, with notable companies identified for potential growth [4][8][5]. Summary by Sections Industry Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biological industry [2]. Market Dynamics - The pharmaceutical sector has shown a year-to-date return of 25.02%, outperforming the Shanghai Composite Index by 18.22 percentage points. The sector's valuation is currently at 27.0 times PE, with a premium of 32.9% compared to the overall A-share market [5][16][8]. Key Company Performance - Notable companies recommended for investment include WuXi Biologics, 3SBio, Changchun High-tech, and others, with their respective stock performances highlighted [2][26][25]. Sector Trends - The report emphasizes the ongoing trend of innovation in pharmaceuticals and medical devices, with specific attention to the GLP-1 drug market and second-generation IO companies, suggesting a rotation of investment opportunities within these segments [4][8][5].